HASBROUCK HEIGHTS, N.J., April 26, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company’s Phase 3 U.S. trials for NX-1207, Nymox’s investigational drug for benign prostatic hyperplasia (BPH). The most recent Safety Monitoring Committee meeting was favorable and indicated no significant safety concerns for the three ongoing U.S. Phase 3 trials to date. Patient recruitment and trial activities for U.S. Phase 3 studies NX02-0017, NX02-0018 and NX02-0020 are ongoing and nearing completion at over 80 well-known urology investigative sites throughout the U.S.
